Liver failure is the most severe form of liver damage caused by viral, alcoholic, drug-related and ischemia-reperfusion factors, often combined with extrahepatic organ damage, resulting in a high mortality rate. This study intends to construct a real-world case registry database of inpatients with liver failure based on an electronic clinical data collection system through a multicenter collaborative network to study the clinical characteristics, epidemiology of bacterial and fungal infections, the impact of sarcopenia on clinical prognosis, and optimization of treatment strategies such as antiviral and artificial liver in Chinese inpatients with liver failure. The cohort and experience generated from this study will be used as a support for a series of future studies to focus on clinical issues such as infection, end-stage liver disease combined with organ failure, and early warning of critically ill patients.
Extreme weakness with significant gastrointestinal symptoms such as anorexia, vomiting and abdominal distention;
Elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) with progressive jaundice (TBil≥85.5 μmol/L);
Bleeding tendency with PTA ≤ 60% or INR ≥ 1.5.
An event or complication that, in the judgment of the investigator, significantly affects the assessment of clinical status.
All patients receive guideline-based systemic therapy. The follow-up assessments will be performed at week 1, 2, 3, 4, 12, 24 and 48 or any time if there is a change in condition. All the patients receive routine biochemical tests and imaging examinations.
Cohort
Other
ALF
Procedure/SurgeryAcute onset, no history of underlying liver disease, liver failure characterized by degree Ⅱ or above hepatic encephalopathy developed within 2 weeks
SALF
Procedure/SurgeryThe onset was acute, with no history of underlying liver disease, and clinical manifestations of liver failure appeared between 2 and 26 weeks
ACLF
Procedure/SurgeryOn the basis of chronic liver disease, the clinical manifestations of acute liver decompensation and liver failure appear in a short period
Overall survival
28-day survival rates without liver transplantation
Overall survival
90-day survival rates without liver transplantation
Disease progression
Incidence of complications and re-hospitalization at 48 weeks after discharge
Click on the lead sponsor to view all of their trials.
